JP2023539574A5 - - Google Patents

Info

Publication number
JP2023539574A5
JP2023539574A5 JP2023512119A JP2023512119A JP2023539574A5 JP 2023539574 A5 JP2023539574 A5 JP 2023539574A5 JP 2023512119 A JP2023512119 A JP 2023512119A JP 2023512119 A JP2023512119 A JP 2023512119A JP 2023539574 A5 JP2023539574 A5 JP 2023539574A5
Authority
JP
Japan
Prior art keywords
seq
residues
less
identity
domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023512119A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023539574A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/046382 external-priority patent/WO2022040239A1/en
Publication of JP2023539574A publication Critical patent/JP2023539574A/ja
Publication of JP2023539574A5 publication Critical patent/JP2023539574A5/ja
Pending legal-status Critical Current

Links

JP2023512119A 2020-08-17 2021-08-17 Shank3遺伝子治療アプローチ Pending JP2023539574A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063066570P 2020-08-17 2020-08-17
US63/066,570 2020-08-17
PCT/US2021/046382 WO2022040239A1 (en) 2020-08-17 2021-08-17 Shank3 gene therapy approaches

Publications (2)

Publication Number Publication Date
JP2023539574A JP2023539574A (ja) 2023-09-15
JP2023539574A5 true JP2023539574A5 (https=) 2024-09-02

Family

ID=77951796

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023512119A Pending JP2023539574A (ja) 2020-08-17 2021-08-17 Shank3遺伝子治療アプローチ

Country Status (11)

Country Link
US (1) US20230340041A1 (https=)
EP (1) EP4196494A1 (https=)
JP (1) JP2023539574A (https=)
KR (1) KR20230051578A (https=)
CN (1) CN116406305A (https=)
AU (1) AU2021328570A1 (https=)
BR (1) BR112023003023A2 (https=)
CA (1) CA3192052A1 (https=)
IL (1) IL300526A (https=)
MX (1) MX2023001998A (https=)
WO (1) WO2022040239A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024178401A1 (en) * 2023-02-24 2024-08-29 Massachusetts Institute Of Technology Shank3 gene therapy approaches
WO2024233422A1 (en) 2023-05-05 2024-11-14 Massachusetts Institute Of Technology Shank3 gene therapy approaches
WO2025217211A1 (en) * 2024-04-08 2025-10-16 Jaguar Gene Therapy, Llc Shank3 potency assay

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5549910A (en) 1989-03-31 1996-08-27 The Regents Of The University Of California Preparation of liposome and lipid complex compositions
US5252334A (en) 1989-09-08 1993-10-12 Cygnus Therapeutic Systems Solid matrix system for transdermal drug delivery
JP3218637B2 (ja) 1990-07-26 2001-10-15 大正製薬株式会社 安定なリポソーム水懸濁液
JP2958076B2 (ja) 1990-08-27 1999-10-06 株式会社ビタミン研究所 遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法
US5741516A (en) 1994-06-20 1998-04-21 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
US5795587A (en) 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US5697899A (en) 1995-02-07 1997-12-16 Gensia Feedback controlled drug delivery system
US5738868A (en) 1995-07-18 1998-04-14 Lipogenics Ltd. Liposome compositions and kits therefor
US5656016A (en) 1996-03-18 1997-08-12 Abbott Laboratories Sonophoretic drug delivery system
US5797898A (en) 1996-07-02 1998-08-25 Massachusetts Institute Of Technology Microchip drug delivery devices
US5783208A (en) 1996-07-19 1998-07-21 Theratech, Inc. Transdermal drug delivery matrix for coadministering estradiol and another steroid
US5779708A (en) 1996-08-15 1998-07-14 Cyberdent, Inc. Intraosseous drug delivery device and method
EP2345731B1 (en) 2003-09-30 2015-10-21 The Trustees of the University of Pennsylvania Adeno-associated virus (AAV) clades, sequences, vectors containing same, and uses thereof
GB201103062D0 (en) 2011-02-22 2011-04-06 Isis Innovation Method
ES2739288T3 (es) 2013-09-13 2020-01-30 California Inst Of Techn Recuperación selectiva
KR102423442B1 (ko) 2015-12-11 2022-07-20 캘리포니아 인스티튜트 오브 테크놀로지 아데노-관련 바이러스를 지시하기 위한 타겟팅 펩타이드
KR102427379B1 (ko) 2016-05-18 2022-08-02 보이저 테라퓨틱스, 인크. 헌팅톤 질환을 치료하기 위한 조성물 및 방법
US20220143214A1 (en) 2019-01-30 2022-05-12 The Broad Institute, Inc. Systems for evolved adeno-associated viruses (aavs) for targeted delivery
IT201900008877A1 (it) * 2019-06-13 2020-12-13 Univ Bologna Alma Mater Studiorum Nuovi costrutti per terapia genica

Similar Documents

Publication Publication Date Title
JP2023539574A5 (https=)
JP2021520203A5 (https=)
JP2023544683A5 (https=)
JP2021505133A5 (https=)
JP2021501130A5 (https=)
JP2020527333A5 (https=)
JP2020520662A5 (https=)
JP2019511570A5 (https=)
JP2014012022A5 (https=)
RU2018129159A (ru) Рекомбинантные aav векторы, экспрессирующие остеопротективные гены, включая has2 и лубрицин, пригодные при лечении остеоартрита и сходных заболеваний суставов у млекопитающих
JP2023504773A5 (https=)
FI4342992T3 (fi) Geenihoito neurodegeneratiivisiin sairauksiin
JP2023535620A5 (https=)
JP2017529395A5 (https=)
JP2020503265A5 (https=)
JP2018538261A5 (https=)
JP2025513851A5 (https=)
JP2023520488A5 (https=)
JP2021525245A5 (https=)
JP2019510047A5 (https=)
JP2022521432A5 (https=)
JP2022501044A5 (https=)
JP2024119830A5 (https=)
JP2024523445A5 (https=)
JP2024133479A5 (https=)